Natalizumab and anti-natalizumab antibody
Natalizumab and anti-natalizumab antibody-15270
Natalizumab and anti-natalizumab antibody
15270
LAB15270
NATAL
Anti-alpha4-integrin inhibitor
biologic therapeutic drug monitoring (TDM)
biological monitoring
immunogenicity testing
Tysabri drug and antibody testing
biologic therapeutic drug monitoring (TDM)
biological monitoring
immunogenicity testing
Tysabri drug and antibody testing
Natalizumab
Anti-natalizumab antibody
Anti-natalizumab antibody
Provides Natalizumab drug and Anti-natalizumab antibody concentrations for pharmacokinetic and immunogenic assessment to optimize treatment. This test may be helpful in any patient on Natalizumab therapy for multiple sclerosis, Crohn's disease or other conditions.
In the presence of Anti-natalizumab antibodies, the Natalizumab level reflects the free antibody-unbound drug level.
This Anti-natalizumab antibody assay is drug tolerant.
Serum
2.0 mL
1.0 mL
Submission of the minimum volume does not allow for repeat testing
Submission of the minimum volume does not allow for repeat testing
Immediately following collection, thoroughly mix sample by gently inverting 5 times
- Allow sample to clot for a minimum of 30 minutes
- Spin within two (2) hours of sample collection
- Transfer serum to a Screw-cap polypropylene frozen transport vial/tube - 4mL (LabCorp), labelled as serum
- Freeze
Frozen (preferred) - 14 days
Refrigerated - 14 days
Ambient - 14 days
Freeze/thaw cycles - stable x 6
LabCorp (505510): R-LC
Weekly
14 days
Electrochemiluminescence Immunoassay (ECLIA)
See report
80299
82397
82397
03/29/2022
06/25/2024
12/21/2023